Over the last few months, AstraZeneca (NYSE: AZN) and Moderna (NASDAQ: MRNA) have emerged as frontrunners in the race for a coronavirus vaccine. Both vaccine efforts are in the midst of the final phase of clinical trials, and both companies are forging international collaborations with competitors, nonprofit groups, and government entities. Early successes have given way to hard setbacks in the clinical development process, yet each contender has rallied to push forward.
Moderna is an unproven biotech without any products on the market, whereas AstraZeneca is a pharmaceutical behemoth with a long history of successful launches. This dynamic is precisely why producing an effective coronavirus vaccine may have dramatically different impacts on each company. Thus, to unpack which is the better coronavirus stock, it’ll be necessary to place each company’s vaccine effort in the context of its competitive position.
AstraZeneca is treading familiar territory with its coronavirus vaccine
AstraZeneca’s SARS-COV-2 vaccine candidate AZD1222 is the only vaccine being developed in the company’s massive pipeline of 166 clinical-stage projects. But AstraZeneca does currently produce a flu vaccine, so it’s hardly a stranger to the later stages of the clinical trial process. Nor is AstraZeneca unfamiliar with maintaining the global supply and distribution chains that will be necessary for mass-scale production. In short, the pharma company has plenty of experience with all of the factors that it needs to operate smoothly to produce a profit from its vaccine.
AstraZeneca’s global operations are already profitable, earning the company $25.7 billion in trailing-12-month revenue. This revenue is highly diversified, as the company’s medicines compete in therapy markets ranging from oncology to neuroscience to gastroenterology. Year-over-year quarterly revenue is also growing at a modest but acceptable rate of 7.8%, driven by AstraZeneca’s development and commercialization of in-demand drug products. If its coronavirus vaccine is approved for sale in major international markets, its revenue could grow substantially, but it’s hard to see how much this growth could significantly change the company’s overall trajectory one way or the other.
After all, AstraZeneca as a company isn’t built around AZD1222. If the vaccine fails, there would no doubt be some fallout for its stock, but that failure wouldn’t reflect on the chances of any of the company’s other pipeline projects, so it wouldn’t be catastrophic. Nor would vaccine failure detract from the company’s existing revenue from established medicine brands, or its revenue growth in newly approved therapies. In the more probable situation where AZD1222 is a success, there’s a good chance that AstraZeneca might end up putting a good portion of the proceeds toward its $22.12 billion of debt, rather than using it to grow.
If Moderna can make its vaccine work, it’ll be on the road to becoming a juggernaut
Moderna’s vaccine, mRNA-1273, is the company’s